[1]Ma YH，Huang YC.Detection of resistance mutations of EGFR gene T90M in peripheral blood of patients with lung adenocarcinoma by different detection methods［D］.Kunming:Kunming Medical University,2014：1-59.［马煜辉，黄云超.不同检测方法在肺腺癌患者外周血ctDNA样本中EGFR基因T90M的耐药突变的研究［D］.昆明：昆明医科大学，2014：1-59.］
[2]Matthew G.Krebs J，Tim H，et al.Circulating tumour cells：Their utility in cancer management and predicting outcomes［J］.Therapeutic Advances in Medical Oncology，2010，2(6)：351-365.
[3]Zhao YP，Zhu RR.The application of circulating tumor cells to analyze the whole process of epithelial-mesenchymal transition of adenocarcinoma and its clinical significance［D］.Beijing:Union Medical College,2016：1-101.［赵玉沛，朱融融.应用循环肿瘤细胞解析膜腺癌上皮-间质转化全程及其临床意义探究［D］.北京：协和医学院，2016：1-101.］
[4]Koeppel F，Blanchard S，Jovelet C，et al.Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients［J］.PLoS One，2017，12(11)：e0188174.
[5]Yang SJ，Wang DD，Li J，et al.Predictive role of GSTP1-containing exosomes in chemotherapy-resistant breast cancer［J］.Gene，2017，623：5-14.
[6]Guo H，Chitiprolu M，Roncevic L，et al.Atg5 Disassociates the V1V0-ATPase to promote exosome production and tumor metastasis independent of canonical macroautophagy［J］.Dev Cell，2017，43(6)：716-730.
[7]Chudasama D，Burnside N，Beeson J，et al.Perioperative detection of circulating tumour cells in patients with lung cancer［J］.Oncol Lett，2017，14(2)：1281-1286.
[8]Nel I，Jehn U，Gauler T，et al.Individual profiling of circulating tumor cell composition in patients with non-small cell lung cancer receiving platinum based treatment［J］.Transl Lung Cancer Res，2014，3(2)：100-106.
[9]Shinsaku Togo，Nobuyoshi Katagiri，Yukiko Namba，et al.Sensitive detection of viable circulating tumor cells using a novel conditionally telomerase-selective replicating adenovirus in non-small cell lung cancer patients［J］.Oncotarget，2017，8(21)：34884-34895.
[10]Pecuchet N，Zonta E，Didelot A，et al.Base-position error rate analysis of next-generation sequencing applied to circulating tumor DNA in non-small cell lung cancer：A prospective study［J］.PLoS Med，2016，13(12)：e1002199.
[11]Yao Yu，Liu Jinghao，Li Lei，et al.Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer［J］.Oncotarget，2017，8(2)：11.
[12]Zhang R,Xia Y，Wang Z，et al.Serum long non coding RNA MALAT-1 protected by exosomes is up-regulated and promotes cell proliferation and migration in non-small cell lung cancer［J］.Biochem Biophys Res Commun，2017，490(2)：406-414.
[13]Schneck H，Gierke B，Uppenkamp F，et al.EpCAM-independent enrichment of circulating tumor cells in metastatic breast cancer［J］.PLoS One，2015，10(12)：e0144535.
[14]Lustberg MB，Balasubramanian P，Miller B，et al.Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients［J］.Breast Cancer Res，2014，16(2)：R23.
[15]Higgins MJ，Jelovac D，Barnathan E，et al.Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood［J］.Clin Cancer Res，2012，18(12)：3462-3469.
[16]Oshiro C，Kagara N，Naoi Y，et al.PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients［J］.Breast Cancer Res Treat，2015，150(2)：299-307.
[17]Chae YK，Davis AA，Jain S，et al.Concordance of genomic alterations by next-generation sequencing in tumor tissue versus circulating tumor DNA in breast cancer［J］.Mol Cancer Ther，2017，16(7)：1412-1420.
[18]Zhao S，Yang H，Zhang M，et al.Circulating tumor cells（CTCs) detected by triple-marker EpCAM，CK19，and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients［J］.Cell Biochem Biophys，2013，65(2)：263-273.
[19]Liu Z，Fusi A，Klopocki E，et al.Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients［J］.J Transl Med，2011，9：70.
[20]Chen Y，Zeng C，Zhan Y，et al.Aberrant low expression of p85alpha in stromal fibroblasts promotes breast cancer cell metastasis through exosome-mediated paracrine Wnt10b［J］.Oncogene，2017，36(33)：4692-4705.
[21]Ning K，Wang T，Sun X，et al.UCH-L1-containing exosomes mediate chemotherapeutic resistance transfer in breast cancer［J］.J Surg Oncol，2017，115(8)：932-940.
[22]Wyatt AW，Annala M，Aggarwal R，et al.Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer［J］.J Natl Cancer Inst，2017，109(12)：1-9.
[23]Wyatt AW，Azad AA，Volik SV，et al.Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer［J］.JAMA Oncol，2016，2(12)：1598-1606.
[24]Antonarakis ES，Lu C，Luber B，et al.Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer［J］.JAMA Oncol，2015，1(5)：582-591.
[25]Conteduca V，Scarpi E，Caroli P，et al.Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer［J］.Sci Rep，2017，7(1)：15541.
[26]Weller P，Nel I，Hassenkamp P，et al.Detection of circulating tumor cell subpopulations in patients with head and neck squamous cell carcinoma（HNSCC)［J］.PLoS One，2014，9(12)：e113706.
[27]Muhanna N，Di MA，Grappa H，et al.Cell-Free DNA kinetics in a pre-clinical model of head and neck cancer［J］.Sci Rep，2017，7(1)：16723.
[28]Deng G，Herrler M，Burgess D，et al.Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients［J］.Breast Cancer Res，2008，10(4)：R69.
[29]El-Gayar D，El-Abd N，Hassan N，et al.Increased free circulating DNA integrity index as a serum biomarker in patients with colorectal carcinoma［J］.Asian Pacific Journal of Cancer Prevention，2016，17(3)：939-944.
[30]Umetani N，Kim J，Hiramatsu S，et al.Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer：Direct quantitative PCR for ALU repeats［J］.Clin Chem，2006，52(6)：1062-1069.
[31]Hao，TB，Shi W，Shen XJ，et al.Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer［J］.Br J Cancer，2014，111(8)：1482-1489.